In summary, metabolic interventions—glutaminase blockade, PPP inhibition, PI3K/mTOR pathway suppression, and AMPK activation—exploit redox vulnerabilities generated by constitutive NRF2 activation, allowing invasive cancers to become more sensitive to oxidative stress and conventional therapy [5,13]. The gene discussed is GLS; the disease is cancer.